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Background: The purpose of the present study was to assess the value for money achieved by bar-retained implant
overdentures based on six implants compared with four implants as treatment alternatives for the edentulous maxilla.
Methods: A Markov decision tree model was constructed and populated with parameter estimates for implant and
denture failure as well as patient-centred health outcomes as available from recent literature. The decision scenario was
modelled within a ten year time horizon and relied on cost reimbursement regulations of the German health care
system. The cost-effectiveness threshold was identified above which the six-implant solution is preferable over the
four-implant solution. Uncertainties regarding input parameters were incorporated via one-way and probabilistic
sensitivity analysis based on Monte-Carlo simulation.
Results: Within a base case scenario of average treatment complexity, the cost-effectiveness threshold was identified
to be 17,564 € per year of denture satisfaction gained above of which the alternative with six implants is preferable over
treatment including four implants. Sensitivity analysis yielded that, depending on the specification of model input
parameters such as patients’ denture satisfaction, the respective cost-effectiveness threshold varies substantially.
Conclusions: The results of the present study suggest that bar-retained maxillary overdentures based on six implants
provide better patient satisfaction than bar-retained overdentures based on four implants but are considerably more
expensive. Final judgements about value for money require more comprehensive clinical evidence including
patient-centred health outcomes.
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Implant-retained overdentures have become an import-
ant treatment option of modern dentistry. Such treat-
ment presents the prospect of high levels of oral health
related quality of life and is particularly important in
times of population aging as edentulousness rates con-
tinue to be relevantly high [1]. For mandibular implant-
based overdentures, current consensus is that patients’
satisfaction and quality of life is significantly greater for
implant-supported overdentures than for conventional
dentures and that a two-implant mandibular overden-
ture should be the minimum treatment standard for
most patients [2]. Not least, the availability of evidence* Correspondence: stefan.listl@med.uni-heidelberg.de
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unless otherwise stated.already facilitated an assessment of the cost-effectiveness
of implant-retained mandibular overdentures [3].
Yet comparably little evidence and consensus seem to
exist with respect to implant-based overdentures for
treatment of the edentulous maxilla. Maxillary overden-
tures have however been considered a relevant treatment
alternative, particularly when retention and stability of
conventional dentures is dissatisfactory [4]. It was sug-
gested that a number of four implants would be the
minimum to support a maxillary overdenture and six
implants would provide additional clinical advantages [5].
In a relevant meta-analysis, most evidence on the clinical
performance of maxillary overdentures was identified to
originate from studies examining either six or four im-
plants connected with a bar [6]. Recently, moreover, some
evidence became available about patient-reported out-
comes of maxillary implant-supported overdentures [7-9].
It yet remains unclear whether the value gained by six. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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dentures outweighs the potentially higher costs.
To our knowledge, the cost-effectiveness of maxillary
overdentures based on six or four implants has never
been investigated before. Therefore, the purpose of the
present study was to assess, on basis of currently available
evidence, the value for money achieved by bar-retained
implant overdentures with six implants compared with
four implants as treatment alternatives for the edentulous
maxilla.
Methods
The present study is based on secondary analysis of pre-
viously published material. Therefore, approval by an
ethics committee was not required. The perspective con-
sidered in this paper is that of a decision maker who
seeks optimization from a societal perspective [10]. Be-
cause social health insurance often does not cover the
expenses of maxillary implant-supported overdentures,
this perspective corresponds closely to the perspective of
the individual patient who wants to understand whether
investment in a six implant overdenture is preferable to
investment in a four-implant overdenture. As such, the
knowledge generated through the present analysis is
likewise relevant for clinical practitioners who want to
inform their patients transparently about suitable treat-
ment alternatives. We assume that the decision making
process is taking place in Germany and model the data
within a Markov decision tree (Figure 1). Markov models
are a health economic technique to depict probabilities
and time durations for cycles in which individuals remain
in the same or move on to different health states. Thereby,
health states are assigned health outcomes and costs, result-
ing in characteristic cost-outcome profiles in response to
treatment decisions [11].
Model input parameters
Implant and denture failure
A literature search via PubMed/Medline (April 9th 2014)
found six meta-analyses for the search terms “maxillary
overdenture”, “upper jaw overdenture”, “implant overden-
ture, maxilla”, “maxillary over-denture”, “upper jaw over-
denture”, and “implant over-denture, maxilla” [5,6,12-15].
From these six meta-analyses, five did not facilitate com-
parisons of various numbers of implants for maxillary
overdentures and were thus excluded from the present
analysis [5,12-15]. The remaining meta-analysis by Slot
et al. [6] was the only one which provided comparisons of
various numbers of implants and respective information
on implant and denture failure. The information from this
study was therefore included for the purpose of our
investigation.
Slot et al. [6] provide information on bar-retained
maxillary implant overdentures after a mean observationperiod of at least one year and report respective failure
rates for dentures combined with either six or four
implants. Based on this information, we modelled the
treatment decision of restoring the edentulous maxilla
by means of a six implant or a four implant based bar-
retained overdenture and defined the respective treat-
ment alternatives as entry points into our Markov model
(Figure 1). For further parameterization of our model we
assumed that, throughout annual cycles of the Markov
model, implants and overdentures could remain either
sound, or an implant failure could occur, or a denture
failure could occur. Thereby, it was assumed that failure
rates occur independent of each other and that implants
are not replaced once lost. The available meta-evidence
provides information for failure rates in relation to six or
four implants only [6]. Therefore, failure rates for other
implant numbers were linearly interpolated. For failure
of dentures without implants, an additional triangular
distribution was assumed. Implant and denture failure
parameters incorporated in the present study are sum-
marized in Table 1.Patient satisfaction
As relevant health outcome parameter, we populated the
Markov decision tree model (Figure 1) with information
about patient satisfaction with overdentures as available
from recent literature. For denture satisfaction in relation
to six and four implants, we relied on overall patient satis-
faction with implant-retained maxillary overdentures as
reported by Slot et al. [8]. Note that this study reports out-
comes for implants located in the posterior maxilla. This
seems justifiable given that a further study reported simi-
lar outcomes for the anterior maxilla and confirmed that
patient satisfaction with dentures does not differ signifi-
cantly between four and six implants [9]. For patients’ sat-
isfaction in relation to two or no implants, we relied on
recently reported findings from Zembic & Wismeijer [7]
on general satisfaction with fitted conventional and two-
implant-retained maxillary dentures. Note that the results
from Slot et al. and from Zembic & Wismeijer were re-
ported on different scales and on basis of different sample
sizes [7,8]. Therefore, the respective parameter values
were included as point estimates and rescaled such that a
value of 1 always indicates perfect satisfaction and zero in-
dicates total dissatisfaction. In order to model denture sat-
isfaction associated with five, three, and one implant(s),
the respective values were linearly interpolated. Moreover,
compromised patient satisfaction due to temporary
denture non-functionality throughout repair periods
was incorporated via a triangularly distributed satisfac-
tion adjustment parameter. Patient satisfaction parameters
incorporated in the present study are summarized in
Table 1.
NB:       chance node; terminal node; decision node; model transition; initial states
Figure 1 The Markov decision tree.
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Table 1 Annual failure rates and health outcome parameters used in the analysis (base case scenario)
Distribution Distribution parameters Data Source
Implant failure
6 implants Triangular Mode 0.018 (min-max 0.014-0.023) [6]
5 implants Triangular Mode 0.0275 (min-max 0.022-0.0345) Interpolated from [6]
4 implants Triangular Mode 0.037 (min-max 0.030-0.046) [6]
3 implants Triangular Mode 0.0465 (min-max 0.038-0.0575) Interpolated from [6]
2 implants Triangular Mode 0.056 (min-max 0.046-0.069) Interpolated from [6]
1 implant Triangular Mode 0.0655 (min-max 0.054-0.0805) Interpolated from [6]
Denture failure
6 implants Triangular Mode 0.026 (min-max 0.015-0.044) [6]
5 implants Triangular Mode 0.0305 (min-max 0.0185-0.0565) Interpolated from [6]
4 implants Triangular Mode 0.035(min-max 0.022-0.069) [6]
3 implants Triangular Mode 0.0395 (min-max 0.0255-0.0815) Interpolated from [6]
2 implants Triangular Mode 0.044 (min-max 0.029-0.094) Interpolated from [6]
1 implant Triangular Mode 0.0485 (min-max 0.0325-0.1065) Interpolated from [6]
no implants Triangular Mode 0.05 (min-max 0.01-0.10) Assumption
Patient satisfaction [1: full satisfaction;
0: no satisfaction]
6 implants Point estimate 0.89 [8]
5 implants Point estimate 0.89 Interpolated from [8]
4 implants Point estimate 0.89 [8]
3 implants Point estimate 0.865 Interpolated from [7,8]
2 implants Point estimate 0.84 [7]
1 implant Point estimate 0.735 Interpolated from [7]
no implants Point estimate 0.63 [7]
Repair period adjustment factor
[1: full satisfaction; 0: no satisfaction]
Triangular Mode 0.9 (min-max 0.8-0.99) Assumption
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As the decision making process was assumed to take place
in Germany, calculation of cost parameters relied on the
relevant reimbursement regulations within the German
health care system. Specifically, the dental personnel costs
associated with provision of new maxillary implant over-
dentures and care after implant loss or denture failure
were calculated in accordance with the “Gebührenordnung
für Zahnärzte” [16,17]. The relevant regulations allow for
consideration of various treatment complexity and re-
quired treatment times for several treatment elements
and, accordingly, different extents of treatment cost. In
the present study, such treatment time variation is imple-
mented via a cost multiplication factor which is assumed
to take on values of 1.0 (low treatment complexity), 2.3
(average treatment complexity), or 3.5 (high treatment
complexity); these multiplication factors are commonly
referred to for cost calculations on basis of the “Gebühre-
nordnung für Zahnärzte” [16]. Cost calculations were
based on information of an online cost calculator (www.
synadoc.de) [18]. Bar constructions and further anchoringelements were assumed to be manufactured out of pre-
dominantly base alloys. Laboratory and material costs for
denture repair were calculated according to the standards
of the Heidelberg University, Department of Prosthodontics
dental lab. Cost parameters incorporated in the present
study are summarized in Table 2.
Measuring ‘value for money’
As it is current practice in the economic evaluation of
dental care [19-27], incremental cost-effectiveness ratios
were employed for comparing additional costs and add-
itional utilities of maxillary overdentures based on six in-
stead of four implants. Estimates of cost and health
outcomes were harvested from the Markov decision tree
model which was assumed to run for ten consecutive cy-
cles, thus representing a ten-year time horizon. To incorp-
orate uncertainties regarding model input parameters,
probabilistic sensitivity analysis was implemented that as-
signs triangular distribution functions to failure rates and
to the adjustment factor for reduced patient satisfaction in
repair periods (Table 1). Monte-Carlo simulations with
Table 2 Cost parameters used in the analysis [in €]
Factor 1.0 Factor 2.3 Factor 3.5 Data source
Dentist labor costs
Six-implant over-denture (new) 1,472.67 2,990.86 4,392.27 [16-18]
Four-implant over-denture (new) 1,130.07 2,199.98 3,190.67 [16-18]
Denture repair after implant failure 206.68 267.35 323.39 [16,17]
Denture repair without implant loss 65.19 84.93 103.16 [16,17]
Material and lab cost
Six-implant over-denture (new) 5,070.30 5070.30 5,070.30 [18]
Four-implant over-denture (new) 4,507.82 4507.82 4,507.82 [18]
Denture repair after implant loss 160.00 160.00 160.00 HU
Denture repair without implant loss 50.00 50.00 50.00 HU
GOZ: Gebührenordnung für Zahnärzte; HU: Heidelberg University, Department of Prosthodontics dental lab.
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Effectiveness-Acceptability-Curves (CEACs) which plot
the probabilities with which the treatment alternative with
six implants and the four-implant solution represent pref-
erable treatment strategies alongside differently assumed
cost-effectiveness threshold levels. Accordingly, thresholds
were gathered above which the preferability of the six-
implant solution exceeds that of the four-implant solution.
In addition to the base case scenario described above, sev-
eral one-way sensitivity analyses were conducted, including
alternative scenarios with respect to patient satisfaction
(defined in Table 3) and with respect to the assumed par-
ameter values for failure of dentures without implants and
for patient satisfaction throughout repair periods. All data
modeling and probabilistic sensitivity analyses were
conducted using the software package TreeAge (TreeAge
Software Inc., Williamstown, MA, USA).
Results
Figure 2 shows the cost-effectiveness scatter-plot based
on Monte-Carlo simulation and incorporating potential
variation in implant and denture survival rates as well
as patient satisfaction in respective after-care periodsTable 3 Alternative patient satisfaction scenarios used







6 implants 0.89 0.89
5 implants 0.85 0.88
4 implants 0.80 0.85
3 implants 0.76 0.82
2 implants 0.72 0.77
1 implant 0.67 0.70
No implants 0.63 0.63(triangular distribution functions as specified in Table 1)
and variation in treatment costs (triangular distribution
function; mode corresponding to cost factor 2.3, mini-
mum value corresponding to cost factor 1.0, maximum
value corresponding to cost factor 3.5; cost calculations as
shown in Table 2). Cost-effectiveness values achieved by
the six-implant solution are represented by red triangles
and cost-effectiveness values achieved by the four-implant
solution are represented by blue circles. The more to the
right on the plane, the higher the utility; the further up on
the plane, the higher the treatment costs. Although the
cost-effectiveness values for both the six-implant solution
and the four-implant solution are scattered widely, there
is a tendency towards the six-implant solution being lo-
cated more to the right and further up on the plane than
the four-implant solution. That means the six-implant so-
lution tends to be more effective but more costly than the
four-implant solution.
Figure 3 shows CEACs for the base case scenario ac-
cording to low treatment complexity (cost multiplication
factor 1.0; Figure 3a), average treatment complexity (cost
multiplication factor 2.3; Figure 3b), and high treatment
complexity (cost multiplication factor 3.5; Figure 3c). All
CEACs follow a similar pattern, that is for low assumed
cost-effectiveness threshold levels the four-implant solu-
tion has a much higher probability of being preferable
than the six-implant solution. With increasing cost-
effectiveness threshold level, the probability of the four-
implant solution to be preferable decreases and that of the
six-implant solution increases such that the six-implant
solution achieves a higher probability to be preferable after
exceeding the intersection point between both CEAC
curves. The respective cost-effectiveness thresholds above
of which the six-implant solution achieves a higher prob-
ability to be preferable over the four-implant solution are
found at 11,746 € per year of denture satisfaction gained
(Figure 3a, cost factor 1.0), 17,546 € per year of denture
satisfaction gained (Figure 3b, cost factor 2.3), and
Figure 2 The cost-effectiveness plane (Monte-Carlo simulation); detailed legend: Monte-Carlo simulation based on distribution functions as
specified in Table 1 and on variation in treatment costs (triangular distribution function; mode corresponding to cost factor 2.3, minimum
value corresponding to cost factor 1.0, maximum value corresponding to cost factor 3.5; cost calculations as shown in Table 2).
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(Figure 3c, cost factor 3.5).
Table 4 displays cost-effectiveness thresholds for the
base case scenario and according to one-way sensitivity
analysis based on altered assumptions about model input
factors (all values are given in € per year of denture satis-
faction gained). These values represent the minimum
monetary amount a decision maker needs to be willing to
invest per additional year of patient’s denture satisfaction
in order to prefer the six-implant solution over the four-
implant solution. Corresponding to the cost-effectiveness
thresholds found in Figure 3 (see above), the base case
scenario presents thresholds of 11,746 € (cost factor 1.0,
low treatment complexity), 17,564 € (cost factor 2.3, aver-
age treatment complexity), and 22,894 € (cost factor 3.5,
high treatment complexity). If assuming different sce-
narios of patient satisfaction as specified in Table 3,
cost-effectiveness thresholds range from 863 € (alterna-
tive scenario A, cost factor 1.0) to 3,420 € (alternative
scenario B, cost factor 3.5). Cost-effectiveness thresholds
remained robust when the annual failure rate of dentureswithout implants was varied from 0.00 to 0.12. Finally,
when alternating the adjustment factor for reduced patient
satisfaction throughout repair periods from 0.0 (total dis-
satisfaction) to 1.0 (complete satisfaction), the respective
cost-effectiveness thresholds ranged from 2,931 € (adjust-
ment factor = 0.0; cost factor 1.0) to 35,040 € (adjustment
factor = 1.0; cost factor = 3.5).
Discussion
This study is, to our knowledge, the first economic evalu-
ation of maxillary implant overdentures so far. Given re-
source scarcity within and outside dental care, results
from such a health economic evaluation may be highly
relevant not only to patients but also to health insurers
and other health care decision makers who need to decide
how resources are best spent in order to increase popula-
tion wellbeing. The question to address is whether relying
on bar-retained maxillary overdentures based on six in-
stead of four implants represents good value for money.
The present study found that, within a ten-year time




Figure 3 Cost-effectiveness acceptability curves (base case
scenario). a) low treatment complexity (cost factor 1.0); b) average
treatment complexity (cost factor 2.3); c) high treatment complexity
(cost factor 3.5).
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dentures based on four implants but at considerably higher
treatment expenses. For a base case scenario of average
treatment complexity, the cost-effectiveness threshold
was identified to be about 17,564 € per year of denture
satisfaction gained above which the alternative with six
implants is preferable over treatment including four
implants. However, sensitivity analysis revealed that cost-
effectiveness thresholds depend considerably on the dis-
tribution of patients’ denture satisfaction as relating to
the number of implants and on the extent of satisfaction
throughout denture repair periods. Plausibly, the prefer-
ability of the six-implant treatment alternative increased
with more pronounced satisfaction margins in compari-
son with the four-implant solution. In addition, because
the probability of denture and implant failure increases
with decreasing number of implants, the preferability of
the six-implant treatment alternative also increased with
more amply constrained satisfaction throughout repair
periods. In order to pinpoint the value for money of
maxillary overdentures based on six instead of four im-
plants more precisely, future research should thus spe-
cifically intend to provide more detailed insights into
patient satisfaction.
Rating the value for money to society in the context of
maxillary implant overdentures is further complicated by
non-availability of relevant reference values, that is
willingness-to-pay (WTP) per year of denture satisfaction
gained. WTP can generally be defined as the maximum a
person would be willing to pay for a good or a service
[28], in this case for one year of satisfaction with an
implant-retained maxillary overdenture. Several methods
exist to measure consumer WTP [29]. These methods can
be distinguished according to whether they measure con-
sumers’ hypothetical or actual WTP, and whether they
measure consumer willingness to pay directly or indirectly
[30]. Methods of measuring WTP include the sealed bid
auction [31], the Vickrey auction [32], conjoint analysis
[33], and contingency valuation [34]. WTP investigations
of oral health care are relatively rare and, so far, have fo-
cused mainly on community water fluoridation [35],
orthognathic treatment [36], anaesthetic gel [37], and
treatment of dentine hypersensitivity [38]. However, it
seems reasonable to contemplate more generic WTP
reference values which are already used by policy makers.
Notably, a threshold range of £20,000 to £30,000 per qual-
ity adjusted life year (QALY) is assumed to be adopted by
national health care decision makers in the United King-
dom [39], corresponding to a threshold range of about
24,000 € to 36,000 € (exchange rate as of April 10th 2014).
Given that societal WTP per year of denture satisfaction
may plausibly be expected to be considerably lower
than societal WTP per QALY, it thus seems unlikely
that a cost-effectiveness threshold of 17,564 € per year
Table 4 Cost-effectiveness thresholds for preferability of six vs. four implants [in € per year of patient satisfaction]
Cost factor 1.0 Factor 2.3 Factor 3.5
Base case 11,746 €/y* 17,564 €/y* 22,894 €/y*
Sensitivity analysis (one-way)
Patient satisfaction
Alternative scenario A (see Table 3) 863 €/y* 1,290 €/y* 1,682 €/y*
Alternative scenario B (see Table 3) 1,755 €/y* 2,624 €/y* 3,420 €/y*
Annual failure rate of denture w/o implants
Failure rate = 0.00 11,746 €/y* 17,564 €/y* 22,894 €/y*
Failure rate = 0.06 11,746 €/y* 17,564 €/y* 22,894 €/y*
Failure rate = 0.12 11,746 €/y* 17,564 €/y* 22,894 €/y*
Repair period satisfaction adjustment factor
Adjustment factor = 0.0 2,931 €/y* 4,382 €/y* 5,712 €/y*
Adjustment factor = 0.2 3,520 €/y* 5,263 €/y* 6,861 €/y*
Adjustment factor = 0.4 4,406 €/y* 6,588 €/y* 8,587 €/y*
Adjustment factor = 0.6 5,887 €/y* 8,803 €/y* 11,474 €/y*
Adjustment factor = 0.8 8,870 €/y* 13,263 €/y* 17,288 €/y*
Adjustment factor = 1.0 17,978 €/y* 26,882 €/y* 35,040 €/y*
*€/y: € per year of denture satisfaction gained.
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for money. Nevertheless, depending on personal pref-
erences and wealth, some patients may still favor the
six-implant alternative to the four-implant solution in
spite of substantially higher costs.
The present study was based on currently available
evidence on clinical and patient-centered outcomes of
implant- and bar-retained maxillary overdentures. We
are aware that a more extensive literature search using
other search engines such as EMBASE or the COCHRANE
library may yield further evidence. Nevertheless, the in-
cluded evidence seems highly representative of the rele-
vant literature and can thus be considered sufficient for
the purpose of the present study, i.e. to provide an eco-
nomic perspective on the value for money gained through
maxillary overdentures based on six as compared to four
implants. The literature in this field appears to be rela-
tively sparse and implies considerable uncertainty regard-
ing the input parameters of our decision analytic model.
In particular, the implant and denture survival rates
underlying our model are based on clinical evidence with
an average follow-up time of only one year and are limited
to information about six and four implants only. In
addition, few studies exist which provide information
about patients’ satisfaction for the relevant clinical scenar-
ios. Given that our results varied substantially with respect
to simulated alterations of model input parameters, more
comprehensive clinical evidence is needed in order to
achieve higher accuracy within health economic evalu-
ation. In the future, this may also better enable to model
more complex clinical scenarios such as different patternsof implant loss or potential re-implantation after implant
loss. In the absence of reliable evidence, we had to assume
that implants are not replaced once lost but this may not
fully capture existing treatment options. In view of consid-
erable uncertainty already implied by currently available
clinical evidence, we also refrained from applying discount
rates to future costs and health outcomes because, gener-
ally, our results may better be understood as providing
guidance for future research priorities rather than very ac-
curate calculations of value for money to the last decimal
point. Nevertheless, the present study established a suit-
able and widely applicable methodological framework for
the economic evaluation of maxillary implant overden-
tures which can be applied in future calculations as well.Conclusion
The results of the present study suggest that bar-retained
maxillary overdentures based on six implants provide bet-
ter patient satisfaction than bar-retained overdentures
based on four implants but are considerably more ex-
pensive. Making final judgments about value for money
however requires more comprehensive clinical evidence
including patient-centered health outcomes. Future clinical
research should specifically examine long-term implant and
denture survival as well as patient-centered outcomes
of different alternatives for implant-retained overdenture
treatment of the edentulous maxilla.Competing interests
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